Momenta and Sandoz fail on US enoxaparin
Executive Summary
Momenta and Sandoz face the prospect of paying treble damages to Amphastar over allegations the two firms “restricted trade and prevented competition in the manufacture and sale of generic enoxaparin” in the US, after a district judge denied Momenta’s bid to dismiss the US-based specialty company’s antitrust lawsuit.
You may also be interested in...
Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement
The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation
Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.